Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-02
2011-08-02
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07989501
ABSTRACT:
The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.
REFERENCES:
patent: WO-94/25429 (1994-11-01), None
R & D Focus Drug News (May 2, 2005).
Sullivan et al., Current Urology Reports, (Jan. 2007), 8/1, pp. 5-11.
S.D. Mertins et al., “In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity”,Molecular Cancer Therapeutics, 3(7), pp. 849-860 (Jul. 2004).
M. Jumaa et al., “Degradation of NSC-281612 (4-[bis[2-[Methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzaldehyde), an Experimental Antineoplastic Agent: Effects of pH, Solvent Composition, (SBE)7mβ-CD, and HP-β-CD on Stability”,Journal of Pharmaceutical Sciences, 93(3) pp. 532-539 (Mar. 2004).
S.D. Mertins et al., “Screening for an Identification of Novel Agents Directed at Renal Cell Carcinoma”,Clinical Cancer Research, vol. 7, pp. 620-633 (Mar. 2001).
Elderfield et al., “Synthesis of Potential Anticancer Compounds. XIV. Methanesulfonic Acid Ester Analogs of Nitrogen Mustards,”J. Organic Chem. 27:573-575, 1962.
Carter et al., “In Vivo Efficacy of an Aldehyde Degradation Product of Dimethane Sulfonate (NSC 281612) in an Orthotopic RXF-393 Human Renal Tumor Model,” 96th Annual Meeting, Apr. 16-20, 2005, Anaheim/Orange County, CA, American Association for Cancer Research (Abstract No. 1381).
Covey et al.., “Preclinical Pharmacokinetics and Metabolism of Benzaldehyde Dimethane Sulfonate (BEN) (NSC 281612),” 96th Annual Meeting, Apr. 16-20, 2005, Anaheim/Orange County, CA, American Association for Cancer Research (Abstract No. 1377).
Bates Susan Elaine
Covell David G.
Hollingshead Melinda G.
Mertins Susan D.
Patton Geoffrey W.
Klarquist & Sparkman, LLP
Spivack Phyllis G.
The United States of America as represented by the Secretary, De
LandOfFree
Treating renal cancer using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating renal cancer using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating renal cancer using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715658